Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting ...
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D. BTIG ...
LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...
Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12. The principal investigator of the clinical trial is ...
Ladies and gentlemen, greetings and welcome to the INmune Bio Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will ...
BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that the ...
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 ...
BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its ...
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United KingdomBOCA ...
INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.26. Operator: Greetings, and welcome to the INmune Bio’s 2025 Fourth Quarter and Year-End Earnings Call. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results